IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082980" target="_blank" >RIV/00216224:14110/15:00082980 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1126/scitranslmed.3010445" target="_blank" >http://dx.doi.org/10.1126/scitranslmed.3010445</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1126/scitranslmed.3010445" target="_blank" >10.1126/scitranslmed.3010445</a>

Result language

angličtina

Original language name

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Original language description

Among patients with colorectal cancer who benefit from therapy targeted to the epidermal growth factor receptor (EGFR), stable disease (SD) occurs more frequently than massive regressions. Exploring the mechanisms of this incomplete sensitivity to devisemore efficacious treatments will likely improve patients' outcomes. We tested therapies tailored around hypothesis-generating molecular features in patient-derived xenografts ("xenopatients"), which originated from 125 independent samples that did not harbor established resistance-conferring mutations. Samples from xenopatients that responded to cetuximab, an anti-EGFR agent, with disease stabilization displayed high levels of EGFR family ligands and receptors, indicating high EGFR pathway activity. Five of 21 SD models (23.8%) characterized by particularly high expression of EGFR and EGFR family members regressed after intensified EGFR blockade by cetuximab and a small-molecule inhibitor.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2015

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

SCIENCE TRANSLATIONAL MEDICINE

ISSN

1946-6234

e-ISSN

—

Volume of the periodical

7

Issue of the periodical within the volume

272

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

"272ra12"

UT code for WoS article

000349422700005

EID of the result in the Scopus database

—